Jens Laigaard

Jens Laigaard

Auto-generated profile, based on publicly available information

Jens Laigaard

Department of Orthopaedic Surgery and Traumatology, Copenhagen University Hospital Bispebjerg, Denmark

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
JLJens Laigaard
Jens Laigaard
CPCasper Pedersen
Casper Pedersen
TRThea Nørgaard Rønsbo
Thea Nørgaard Rønsbo
OMOle Mathiesen
Ole Mathiesen
AKAnders Peder Højer Karlsen
Anders Peder Højer Karlsen

20 August 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AKAnders Karlsen
Anders Karlsen
SWSebastian Wiberg
Sebastian Wiberg
JLJens Laigaard
Jens Laigaard
CPCasper Pedersen
Casper Pedersen
KRKim Zillo Rokamp
Kim Zillo Rokamp
OMOle Mathiesen
Ole Mathiesen
To identify investigated interventions for COVID-19 prevention or treatment via trial registry entries on planned or ongoing randomised clinical trials. To assess these registry entries for recruitment status, planned trial size, blinding and reporting of mortality. We identified trial registry entries systematically via the WHO International Clinical Trials Registry Platform and 33 trial registries up to June 23, 2020. We included relevant trial registry entries for randomized clinical trials investigating medical preventive, adjunct or supportive therapies and therapeutics for treatment of COVID-19. Studies with non-random and single-arm design were excluded. Trial registry entries were screened by two authors independently and data were systematically extracted. We included 1303 trial registry entries from 71 countries investigating 381 different single interventions. Blinding was planned in 47% of trials. Sample size was >200 participants in 40% of trials and a total of 611,364 participants were planned for inclusion. Mortality was listed as an outcome in 57% of trials. Recruitment was ongoing in 54% of trials and completed in 8%. Thirty-five percent were multicenter trials. The five most frequent investigational categories were immune modulating drugs (266 trials (20%)), unconventional medicine (167 trials (13%)), antimalarial drugs (118 trials (9%)), antiviral drugs (100 trials (8%)) and respiratory adjuncts (78 trials (6%)). The five most frequently tested uni-modal interventions were: chloroquine/hydroxychloroquine (113 trials with 199,841 participants); convalescent plasma (64 trials with 11,840 participants); stem cells (51 trials with 3,370 participants); tocilizumab (19 trials with 4,139 participants) and favipiravir (19 trials with 3,210 participants). An extraordinary number of randomized clinical trials investigating COVID-19 management have been initiated with a multitude of medical preventive, adjunctive and treatment modalities. Blinding will be used in only 47% of trials, which may have influence on future reported treatment effects. Fifty-seven percent of all trials will assess mortality as an outcome facilitating future meta-analyses.

21 February 2024 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Open access
AKAnders Karlsen
Anders Karlsen
JLJens Laigaard
Jens Laigaard
CPCasper Pedersen
Casper Pedersen
KTKasper Højgaard Thybo
Kasper Højgaard Thybo
KGKasper Smidt Gasbjerg
Kasper Smidt Gasbjerg
OMOle Mathiesen
Ole Mathiesen
Background: Morphine‐sparing effects are often used to evaluate non‐opioid analgesic interventions. The exact effect that would warrant the implementation of these interventions in clinical practice (a minimally important difference) remains unclear. We aimed to determine this with anchor‐based methods.Methods: This was a post hoc analysis of three studies investigating pain management after hip or knee arthroplasty (PANSAID [NCT02571361], DEX‐2‐TKA [NCT03506789] and Pain Map [NCT02340052]). The overall population was median aged 70, median ASA 2, 54% female. We examined the correlation between 0 and 24 h postoperative iv morphine equivalent consumption and the severity of nausea, vomiting, sedation and dizziness. The anchor was different severity degrees of these opioid‐related adverse events. The primary outcome was the difference in morphine consumption between patients experiencing no versus only mild events. Secondary outcomes included the difference in morphine consumption between patients with mild versus moderate and moderate versus severe events. We used Hodges–Lehmann median differences, exact Wilcoxon–Mann–Whitney tests and quantile regression.Results: The difference in iv morphine consumption was 6 mg (95% confidence interval: 4–8) between patients with no versus only mild events, 5 mg (2–8) between patients with mild versus moderate events and 0 mg (−4 to 4) between patients with moderate versus severe events.Conclusions: In populations comparable to this post‐hoc analysis (orthopaedic surgery, median age 70 and ASA 2), we suggest a minimally important difference of 5 mg for 0–24 h postoperative iv morphine consumption.

6 November 2025 in European journal of pain
Verified
Journal Article
Closed access
ASAtena Saito
Atena Saito
JLJens Laigaard
Jens Laigaard
PSPernille Bjersand Sunde
Pernille Bjersand Sunde
CFCaroline Folkersen
Caroline Folkersen
IRIda Houtved Rasmussen
Ida Houtved Rasmussen
AKAnders Karlsen
Anders Karlsen

17 October 2024 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
JLJens Laigaard
Jens Laigaard
AKAnders Karlsen
Anders Karlsen
MMMathias Maagaard
Mathias Maagaard
TLTroels Haxholdt Lunn
Troels Haxholdt Lunn
OMOle Mathiesen
Ole Mathiesen
SOSøren Overgaard
Søren Overgaard
BACKGROUND: High pain levels immediately after surgery have been associated with persistent postsurgical pain. Still, it is uncertain if analgesic treatment of immediate postsurgical pain prevents the development of persistent postsurgical pain. METHODS: We searched MEDLINE, CENTRAL, and Embase up to September 12, 2023, for randomized controlled trials investigating perioperative analgesic interventions and with reported pain levels 3 to 24 months after total hip or knee arthroplasty in patients with osteoarthritis. The primary outcome was pain score 3 to 24 months after surgery, assessed at rest and during movement separately. Two authors independently screened, extracted data, and assessed risk of bias using the Cochrane Risk of Bias 2 tool. We conducted meta-analyses and tested their robustness with trial sequential analyses and worst-best and best-worst case analyses. RESULTS: We included 49 trials with 68 intervention arms. All but 4 trials were at high risk of bias for the primary outcome. Moreover, the included trials were heterogeneous in terms of exclusion criteria, baseline pain severity, and which cointerventions the participants were offered. For pain at rest, no interventions demonstrated a statistically significant difference between intervention and control. For pain during movement, perioperative treatment with duloxetine (7 trials with 641 participants) reduced pain scores at 3 to 24 months after surgery (mean difference −4.9 mm [95% confidence interval {CI}, −6.5 to −3.4] on the 0–100 visual analog scale) compared to placebo. This difference was lower than our predefined threshold for clinical importance of 10 mm. CONCLUSIONS: We found no perioperative analgesic interventions that reduced pain 3 to 24 months after total hip or knee arthroplasty for osteoarthritis. The literature on perioperative analgesia focused little on potential long-term effects. We encourage the assessment of long-term pain outcomes.

27 October 2025 in Acta Orthopaedica
Verified
Journal Article
Open access
PDF file
JLJens Laigaard
Jens Laigaard
SASaber M Aljuboori
Saber M Aljuboori
LNLone Nikolajsen
Lone Nikolajsen
OMOle Mathiesen
Ole Mathiesen
TLTroels H Lunn
Troels H Lunn
SOSøren Overgaard
Søren Overgaard
Background and purpose: Contemporary data on the risk of chronic pain after total knee arthroplasty (TKA) and unicompartmental knee arthroplasty (UKA) is limited. Therefore, we aimed to investigate the incidence of chronic pain, pain characteristics, patterns of analgesic use, patient satisfaction, and willingness to undergo the same surgery again, 1 year after primary TKA and UKA for osteoarthritis.Methods: We conducted a nationwide online survey among unselected patients who underwent primary TKA or medial UKA for primary osteoarthritis in Denmark. At 1 year postoperatively, we assessed the incidence of moderate to severe pain (≥ 4 on the 0–10 numerical rating scale), frequency of pain, pain interference with everyday life, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain domain, the Douleur Neuropathique 4 interview (DN4i), use of analgesics, satisfaction, and willingness to undergo the same surgery again.Results: We sent survey invitations to 2,580 TKA patients and 1,007 UKA patients who underwent surgery in 2022. Of the 70% TKA respondents, 25% had moderate to severe chronic pain, 82% were satisfied/very satisfied with the result of surgery, and 86% indicated that they would choose to undergo surgery again. Of the 75% UKA respondents, 23% had moderate to severe chronic pain, 86% were satisfied/very satisfied, and 88% would undergo the same surgery again.Conclusion: In Denmark, 25% of TKA patients and 23% of medial UKA patients experienced moderate to severe knee pain after 1 year. These numbers were higher than most previous estimates. Most patients were satisfied with the result of surgery and would undergo the same surgery again.